Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD) (IMPAEPOC)

AstraZeneca

Status: Completed

Conditions: COPD

Study type: Observational

Funder types: Industry

Identifiers

NCT01266395

NIS-RES-DUM-2010/2

Details and patient eligibility

About

Observational study to know the Impact of morning symptoms in clinical control of COPD patients. 1200 patients will be included by General practitioners (GPs) and pneumologists. Objective: establish if there are differences in the impact of COPD on daily activities and morning symptoms measured through questionnaires of daily life activity (Capacity of Daily Living during the Morning (CDLM), Global Chest Symptoms Questionnaire (GCSQ))

Enrollment: 1,268 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient has signed informed consent form

• Patients of both sexes,> 40 years.

• Patients diagnosed with COPD according to global consensus on the definition, classification and management of the disease (GOLD) criteria:

  • post-bronchodilator forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) <70%
  • post-bronchodilator FEV1 <80% (stage II, III and IV)

Exclusion criteria

• Participating in an epidemiological study or clinical trial
• Patient with other respiratory disease than COPD (eg bronchial asthma, cystic fibrosis, severe bronchiectasis, restrictive lung disease, cancer, etc.).
• Patients with mild COPD: FEV1> 80%